HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

(2014) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

(2013) Alexa B. Kimball et al.   ANNALS OF INTERNAL MEDICINE

Pathogenesis and pharmacotherapy of Hidradenitis suppurativa

(2011) Maiwand Nazary et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A?systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis

(2011) Amanda Robinson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity

(2009) K. Sartorius et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY